Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0272-6386(12)80068-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Causal inference can lead us to modifiable mechanisms and informative archetypes in sepsis.
Intensive Care Med
December 2024
International Sepsis Forum, Murphy, NC, USA.
Medical progress is reflected in the advance from broad clinical syndromes to mechanistically coherent diagnoses. By this metric, research in sepsis is far behind other areas of medicine-the word itself conflates multiple different disease mechanisms, whilst excluding noninfectious syndromes (e.g.
View Article and Find Full Text PDFA case of de novo glomerulonephritis following COVID-19 in a patient with preexistent IgA vasculitis.
CEN Case Rep
October 2024
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Article Synopsis
- * A case study discusses a young Japanese woman with preexisting IgAV who developed glomerulonephritis after contracting COVID-19, experiencing symptoms like hematuria and proteinuria following her illness.
- * After a renal biopsy confirmed her condition, she was treated with corticosteroids and showed significant improvement, indicating that COVID-19 may provoke kidney issues in IgAV patients without prior renal symptoms.
Rapid achievement of low-density lipoprotein cholesterol goals within 1 month after acute coronary syndrome during combination therapy with rosuvastatin, ezetimibe and bempedoic acid: Initial experience from the LAI-REACT study.
J Clin Lipidol
November 2024
Heart Disease Prevention Program Division of Cardiology, University of California Irvine School of Medicine, Irvine, California, USA (Dr Wong).
Article Synopsis
- Rapid LDL-C reduction post-acute coronary syndrome (ACS) is crucial for future event prevention, but high-dose statins alone often don't meet LDL-C targets.
- Combining rosuvastatin, ezetimibe, and bempedoic acid (REB) in a study showed significant LDL-C decreases from baseline levels, achieving reductions within just one week.
- The triple therapy allowed over 76% of patients to reach recommended LDL-C levels quickly, making it a viable and affordable option for treatment in India.
Single-cell multi-omic and spatial profiling of human kidneys implicates the fibrotic microenvironment in kidney disease progression.
Nat Genet
August 2024
Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Kidneys are intricate three-dimensional structures in the body, yet the spatial and molecular principles of kidney health and disease remain inadequately understood. We generated high-quality datasets for 81 samples, including single-cell, single-nuclear, spot-level (Visium) and single-cell resolution (CosMx) spatial-RNA expression and single-nuclear open chromatin, capturing cells from healthy, diabetic and hypertensive diseased human kidneys. Combining these data, we identify cell types and map them to their locations within the tissue.
View Article and Find Full Text PDFEffect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes.
Diabetes Res Clin Pract
July 2024
Department of Medicine, Division of Nephrology, University Health Network, 585 University Avenue, Toronto, Ontario M5G 2N2, Canada; Temerty Faculty of Medicine, University of Toronto, 2109 Medical Sciences Building, 1 King's College Cir, Toronto, Ontario M5S 1A8, Canada; Cardiovascular Sciences Collaborative Specialization, University of Toronto, 263 McCaul St, P.O. Box 3C, 4th Floor, Rm 413, Toronto, Ontario M5T 1W7, Canada. Electronic address:
Aims: To investigate the effect of hyperglycemia and empagliflozin on cardiorenal injury and inflammation in patients with uncomplicated type 1 diabetes (T1D).
Methods: Serum cardiac (sST2, Gal-3, cTnT), kidney injury (KIM-1, NGAL), inflammatory (sTNFR1, sTNFR2), and hemodynamic (NT-proBNP, EPO) markers were assessed post-hoc in two separate T1D cohorts. The glycemic clamp trial (NCT02344602) evaluated 49 adults with T1D and 27 controls under euglycemic and acute hyperglycemic conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!